Cited by 808Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis MechanismsAtrial Fibrillation Management and Outcomes

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

Open access

Ridker, Paul M, Goldhaber, Samuel Z., Danielson, Ellie, Rosenberg, Yves, Eby, Charles S., Deitcher, Steven R., Cushman, Mary, Moll, Stephan, Kessler, Craig M., Elliott, C. Gregory, Paulson, Rolf, Wong, Turnly, Bauer, Kenneth A., Schwartz, Bruce A., Miletich, Joseph P., Bounameaux, Henri, Glynn, Robert J.·2003·New England Journal of Medicine

DOI 10.1056/nejmoa035029

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Standard therapy to prevent recurrent venous thromboembolism includes 3 to 12 months of treatment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio. METHODS: Patients with idiopathic venous thromboembolism who had received full-dose anticoagulation therapy for a median of 6.5 months were randomly assigned to placebo or low-intensity warfarin (target INR, 1.5 to 2.0). Participants were followed for recurrent venous thromboembolism, major hemorrhage, and death. RESULTS: The trial was terminated early after 508 patients had undergone randomization and had been followed for up to 4.3 years (mean, 2.1). Of 253 patients assigned to placebo, 37 had recurrent venous thromboembolism (7.2 per 100 person-years), as compared with 14 of 255 patients assigned to low-intensity warfarin (2.6 per 100 person-years), a risk reduction of 64 percent (hazard ratio, 0.36 [95 percent confidence interval, 0.19 to 0.67]; P<0.001). Risk reductions were similar for all subgroups, including those with and those without inherited thrombophilia. Major hemorrhage occurred in two patients assigned to placebo and five assigned to low-intensity warfarin (P=0.25). Eight patients in the placebo group and four in the group assigned to low-intensity warfarin died (P=0.26). Low-intensity warfarin was thus associated with a 48 percent reduction in the composite end point of recurrent venous thromboembolism, major hemorrhage, or death. According to per-protocol and as-treated analyses, the reduction in the risk of recurrent venous thromboembolism was between 76 and 81 percent. CONCLUSIONS: Long-term, low-intensity warfarin therapy is a highly effective method of preventing recurrent venous thromboembolism.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa035029

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,769
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
Poort, S., Rosendaal, F. R., Reitsma, P. H., & Bertina, R. M. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,045
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,094
Resistance to Activated Protein C as a Basis for Venous Thrombosis
Svensson, P. J., & Dahlbäck, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199402243300801 · Cited by 1,127
A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism
Kearon, C., Gent, M., Hirsh, J., Weitz, J. I., Kovacs, M. J., Anderson, D. R., Turpie, A. G. G., Green, D., Ginsberg, J. S., Wells, P. S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,057
Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
Ridker, P. M., Hennekens, C. H., Lindpaintner, K., Stampfer, M. J., Eisenberg, P. R., & Miletich, J. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504063321403 · Cited by 1,031
Self-citation
A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Very Low Doses of Warfarin Can Prevent Thrombosis in Central Venous Catheters
Bern, M. M., Lokich, J. J., Wallach, S. R., Bothe, A., Benotti, P. N., Arkin, C. F., Greco, F. A., Huberman, M., & Moore, C. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-423 · Cited by 787

Show all 29 references

Research works printed but not linked: 2

Kearon C, 2002, Blood, 100, 150a
Eriksson H, 2002, Blood, 100, 81a

Sorted by citations

Items 601–700 of 807

Hemostasis and Anticoagulation Therapy
Mourão, M. S. F., CENEDEZI, J. M., Machado, J. E. P., Ferreira, J. C. D., & Junqueira, D. R. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-46059-8_4 · Cited by 2
Hereditary and Acquired Thrombophilia
Riess, H. B. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-287-8_15 · Cited by 2
Traitement de la maladie thromboembolique veineuse
Sanchez, O., Wermert, D., Allain, Y., Sors, H., & Meyer, G. (2005) · La Presse Médicale · doi:10.1016/s0755-4982(05)84204-6 · Cited by 2
Can anticoagulant treatment be tailored with biomarkers in patients with venous thromboembolism?
Kamphuisen, P. W. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01931.x · Cited by 2
Thromboembolism and thrombophilia
Girling, J. (2004) · Current Obstetrics and Gynaecology · doi:10.1016/j.curobgyn.2003.10.001 · Cited by 2
Low intensity warfarin: is it clinically useful in venous thromboembolism management?
Bauer, K. A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05174.x · Cited by 2
“The Prevention of Recurrent Venous Thromboembolism (PREVENT) trial, performed at sites primarily in the US, compared low-intensity warfarin (INR 1Æ5–2) with placebo in 508 patients (Ridker et al, 2003).”
MethodSelf-citation
Emerging strategies for treatment of venous thromboembolism
Prandoni, P. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.1.87 · Cited by 2
Trombosis venosa profunda: consideraciones terapéuticas
Vicente, V., & Almela, M. L. L. (2005) · Revista Clínica Española · doi:10.1157/13070750 · Cited by 2
The Future of Medical Therapy for Venous Thromboemboli
Caprini, J. A. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.08.005 · Cited by 2
Pregnancy-related thrombosis and thrombophilia update: a case for prevention
Rosene‐Montella, K. (2003) · Journal of Obstetrics and Gynaecology · doi:10.1080/0144361031000156519 · Cited by 2
“A recent secondary prevention trial randomising patients to low-intensity warfarin vs. placebo after 53 months of treatment demonstrated a 64% risk reduction for recurrence in the treated group (Ridker et al., 2003).”
Background
The Use of Pharmacoepidemiology to Study Beneficial Drug Effects
Strom, B. L., & Melmon, T. L. K. L. (2019) · Pharmacoepidemiology · doi:10.1002/9781119413431.ch33 · Cited by 2
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Tran, H. A., McRae, S. J., & Ginsberg, J. S. (2006) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2005.09.004 · Cited by 1
“The annual risk of major bleeding when warfarin is adjusted to achieve a target INR of 2 to 3 is 1% to 3% [77,88,89,136].”
Background
Effectiveness of a self-management program for anticoagulated patients to improve their knowledge about treatment and time in therapeutic range
Romero-Arana, A., González-Rodríguez, M. J., Sánchez-Vega, P., Gómez-Salgado, J. C., & Ruiz, A. R. (2024) · Medicine · doi:10.1097/md.0000000000040258 · Cited by 1
“[6] Heart valve prostheses (especially those of the metallic type) and fibrinolysis disorders also require lifelong treatment, very usually monitored by nurses.”
Background
Contraceptive Options for Women with Thrombophilia and Thromboembolic Disease
Salcedo, J., Sridhar, A., & Rizack, T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1233-9_12 · Cited by 1
Idiopathic Venous Thromboembolism
Sinescu, C. J. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4429-8_20 · Cited by 1
Venous thromboembolic disease.
Jaff, M. R. (2002) · PubMed Central · Cited by 1
Prolongation d’un traitement par anti-vitamine K (AVK) pendant 18 mois versus placebo au décours d’un premier épisode d’embolie pulmonaire idiopathique traité six mois : un essai randomisé multicentrique en double insu. Essai « PADIS-EP » PHRC national 2006
Couturaud, F. (2008) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2008.09.012 · Cited by 1
Pronostic et suivi à long terme de la maladie thromboembolique veineuse
Pinède, L. (2007) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/s1261-694x(07)92132-x · Cited by 1
Recent advances in the diagnosis and treatment of pulmonary thromboembolism
Kucher, N., & Goldhaber, S. Z. (2003) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.09.066 · Cited by 1
Self-citation
Consenso intersociedades español sobre el diagnóstico, estratificación de riesgo y tratamiento de pacientes con tromboembolia pulmonar
Jiménez, D., & Uresandi, F. (2014) · Angiología · doi:10.1016/j.angio.2014.02.003 · Cited by 2
Extended Therapy for Primary and Secondary Prevention of Venous Thromboembolism
Conway, S. E., & Marcy, T. R. (2010) · Journal of Pharmacy Practice · doi:10.1177/0897190010366930 · Cited by 1
Aspirin given for up to 2 years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding
Watson, H. G. (2012) · Evidence-Based Nursing · doi:10.1136/eb-2012-100896 · Cited by 1
Diagnostik und Therapie der Rezidivthrombose
Blättler, W., & Gerlach, H.-E. (2006) · Gefässchirurgie · doi:10.1007/s00772-005-0443-y · Cited by 1
What's New About Old Drugs
Linnebur, S. A. (2004) · Journal of Gerontological Nursing · doi:10.3928/0098-9134-20040101-04 · Cited by 1
Long-term therapy of pulmonary embolism.
Agnelli, G., & Becattini, C. (2005) · PubMed · Cited by 1
Durée optimale du traitement anticoagulant au décours d’une embolie pulmonaire
Tromeur, C., & Couturaud, F. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.07.005 · Cited by 1
“[39] Ridker PM, Goldhaber SZ, Danielson E, et al.”
BackgroundInfluential
Therapy of venous thromboembolism: anticoagulant treatment
Bounameaux, H., & Righini, M. (2006) · Kardiovask Med · doi:10.4414/cvm.2006.01158 · Cited by 1
Self-citation
Derin ven trombozu bulunan hastalarda tedavi etkinliğinin değerlendirilmesi
Gür, Ö., Gürkan, S., Çakır, H., Gür, D. Ö., Donbaloğlu, M. O., & Ege, T. (2012) · DergiPark (Istanbul University) · doi:10.17826/cutf.98527 · Cited by 1
Venous thromboembolism in the elderly
Ploenes, C. (2016) · Phlebologie · doi:10.12687/phleb2315-4-2016 · Cited by 1
“showed that, compared with placebo, the VTE recurrence rate could be reduced by 64 % (relative risk) with no increase in the risk of bleeding (29).”
Background
Venous Thrombosis
Weitz, J. I., & Eikelboom, J. W. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2930-6.00052-5 · Cited by 1
Anticoagulación extendida en la enfermedad tromboembólica venosa. A favor
Capitán, M. C. F. (2017) · Revista Clínica Española · doi:10.1016/j.rce.2017.02.017 · Cited by 1
The Genetics of Thrombosis
Shah, S. H., & Becker, R. C. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-235-3_4 · Cited by 1
Anticoagulation for Proximal Deep Vein Thrombosis
Lee, A. I., & Lee, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-65226-9_23 · Cited by 1
Long term use of anticoagulant therapy for patients with pulmonary embolism
Becattini, C., & Cimini, L. A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1770589 · Cited by 1
“Two randomized studies were conducted with VKAs at subtherapeutic doses after the initial 3 to 6 months of conventional anticoagulation (Figure 1) [14,15].”
Background
Epidemiologic study of patients with thrombotic events referred to a tertiary hospital in Southern Iran
Akbari, A., Haghpanah, S., Barzegar, H., Shahsavani, A., Afrasiabi, A., Parand, S., & Karimi, M. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e07734 · Cited by 1
Venous Disease
Goldhaber, S. Z. (2007) · Springer eBooks · doi:10.1007/978-1-84628-715-2_82 · Cited by 1
Self-citation
Anticoagulation for Venous Thromboembolism
Ortel, T. L. (2013) · Springer eBooks · doi:10.1007/978-3-319-01812-6_21 · Cited by 1
Trombosi venosa: diagnosi e trattamento
Delsart, D., Girard, G., Moulin, N., Rivron-Guillot, K., & Decousus, H. (2008) · EMC - Urgenze · doi:10.1016/s1286-9341(08)70021-8 · Cited by 1
Seguimiento de la tromboembolia pulmonar
Uresandi, F., Iruín, G., Gómez, B., & Uresandi, A. (2008) · Medicina Clínica · doi:10.1016/s0025-7753(08)76450-9 · Cited by 1
Diagnosis and therapy in cancer-associated thromboembolism – what about guideline recommendations?
Matzdorff, A. C. (2015) · Phlebologie · doi:10.12687/phleb2288-6-2015 · Cited by 1
Progrès diagnostiques et thérapeutiques
Genest, M., & Pochmalicki, G. (2004) · La Presse Médicale · doi:10.1016/s0755-4982(04)98690-3 · Cited by 1
NEW PROSPECTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOSIS
Laguta, P. S. (2016) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2016-1-5-15 · Cited by 1
Extended anticoagulation in venous thromboembolism disease. In favor
Fernández, M. C. (2017) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.04.003 · Cited by 1
Real world experience at a single centre using low dose direct oral anticoagulants after unprovoked venous thromboembolism
Thomas, W., Symington, E. M., Besser, M. W., & Sheares, K. K. K. (2019) · British Journal of Haematology · doi:10.1111/bjh.15880 · Cited by 1
“The VTE recurrence rate reported here is comparable to two large historical trials using standard intensity warfarin, where recurrence rates of 0 7/100 patient years and 2 6/100 patient years, respectively, were reported (Kearon et al, 2003; Ridker et al, 2003).”
Result
Comparative efficacy of long-term anticoagulation in patients with iliofemoral acute deep vein thrombosis treated with pharmaco-mechanical catheter-directed thrombolysis
Günaydın, S., Budak, A. B., Günertem, E., Tümer, N. B., Kunt, A. T., & Özışık, K. (2020) · Turkish Journal of Clinics and Laboratory · doi:10.18663/tjcl.796973 · Cited by 1
Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials
Wang, W., Su, Y., Wu, C., Sun, Y., Dai, N., Chen, W., Zhang, J., Xu, Y., Brindis, R. G., Xu, D., et al. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01345-z · Cited by 1
Sex differences in thromboprophylaxis of the critically ill: a secondary analysis of a randomized trial
Burns, K. E. A., Heels‐Ansdell, D., Thabane, L., Kahn, S. R., Lauzier, F., Mehta, S., Ostermann, M., Bhuptani, P., Crowther, M. A., Finfer, S. R., et al. (2023) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-023-02457-8 · Cited by 2
An investigation of the effects of fulvic and humic acids on the absorption of selected drugs, vitamins and minerals using the everted mouse gut model
Willis, K. (2015) · UpSpace Institutional Repository (University of Pretoria) · Cited by 1
Trombofilia venosa. Clasificaci?n, implicaciones cl?nicas y terap?uticas
Villamediana, R. L., Antn, M. P. S., Snchez, J. F., & Hernando, E. R. (2004) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(04)70214-3 · Cited by 1
Continuing Anticoagulation Following Venous Thromboembolism—Reply
Ost, D. E. (2005) · JAMA · doi:10.1001/jama.294.24.3088-b · Cited by 1
Extension of anticoagulation after venous thromboembolism
Schulman, S. (2008) · Hämostaseologie · doi:10.1055/s-0037-1617168 · Cited by 1
Duration of Anticoagulation in Venous Thromboembolism
Hyers, T. M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.11.1265 · Cited by 1
Update in thrombosis: answers to perplexing questions.
Federman, D. G., Brescia, G., Moriarty, J. P., Haskell, S. G., Krishnamurthy, R., & Kirsner, R. S. (2005) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.72.10.907 · Cited by 1
Maladie veineuse thrombo-embolique
Tromeur, C. (2012) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(12)70341-5 · Cited by 1
The Burden of Rate Control in Atrial Fibrillation
Kumana, C. R., Cheung, B. M. Y., & Lauder, I. J. (2003) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840300800310 · Cited by 1
Studies on warfarin treatment with emphasis on inter-individual variations and drug monitoring
Osman, A. (2007) · DiVA (Linkoping University) · Cited by 1
Genetically Determined Procoagulant States and Heparin Use
McBane, R. D. (2003) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/108925320300700407 · Cited by 1
Ximelagatran for Secondary Prevention of Venous Thromboembolism
Vaknansky, A., Kupfer, Y. Y., & Tessler, S. (2004) · New England Journal of Medicine · doi:10.1056/nejm200402053500619 · Cited by 1
Long‐term management of venous thromboembolism: is there a role for low‐intensity warfarin therapy?
Eikelboom, J. W., & Hankey, G. J. (2003) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05436.x · Cited by 1
d -Dimer and Duration of Anticoagulation
Pernod, G., Sevestre, M., & Labarère, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmc063267 · Cited by 1
[Diagnosis and treatment of venous thrombosis].
Hach-Wunderle, V. (2005) · PubMed · Cited by 1
Antikoagulationstherapie bei venöser Thromboembolie
Beyer, J., & Schellong, S. (2008) · Herz · doi:10.1007/s00059-008-3087-3 · Cited by 1
Pulmonary Embolism
Kucher, N., & Goldhaber, S. Z. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0284-4.50060-9 · Cited by 1
Self-citation
Deep Vein Thrombosis and Pulmonary Embolism
Goldhaber, S. Z. (2007) · Elsevier eBooks · doi:10.1016/b978-141602401-9.10015-x · Cited by 1
Self-citation
References
(2007) · CRC Press eBooks · doi:10.1201/9781420005127.bmatt1 · Cited by 1
Treatment and management of acute venous thromboembolic disease
Comp, P. C. (2003) · Thrombosis Research · doi:10.1016/s0049-3848(03)00349-9 · Cited by 1
New developments in diagnosis and treatment of deep vein thrombosis
ten Cate‐Hoek, A. J. (2008) · doi:10.26481/dis.20081010ac · Cited by 1
Use of Chronic Anticoagulation in the Elderly: A Review of the Benefits and Risks
O'Donnell, M. J. (2004) · Developments in cardiovascular medicine · doi:10.1007/978-1-4419-8865-2_9
Pathologie Veineuse Aiguë
Luizy, F. (2011) · Elsevier eBooks · doi:10.1016/b978-2-294-71346-0.50001-x · Cited by 1
Neue Aspekte zur Therapie der venösen Thromboembolie
Stümpflen, A. (2004) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Varfariinravi tõhususe ja ohutuse analüüs eakatel patsientidel perearsti praktikas
Gavronski, M., & Žarkovski, A. (2014) · Ajakirjad. Journals by UT · doi:10.15157/ea.v0i0.10622
Common clinical indications for anticoagulation
Krishnamoorthy, S., Khoo, C. W., Shantsila, E., & Lip, G. Y. H. (2010) · doi:10.1007/978-1-908517-08-1_2
Therapie der postoperativen Thrombose
Linke, L. C. (2009) · Der Orthopäde · doi:10.1007/s00132-009-1451-5
Clinical and biochemical risk factors for first and recurrent episodes of venous thrombosis
Christiansen, S. C. (2010) · Leiden Repository (Leiden University)
Antithrombotische Therapie bei Patienten mit Indikation zur oralen Antikoagulation und koronarer Stentimplantation
Zeymer, U., Senges, J., & Zahn, R. (2009) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-009-0069-9
Thrombophilia, Thromboembolic Disease, and Antithrombotic Therapy
Hiller, E. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-149-9_21
Estudo da trombose microvascular em biópsias pulmonares de pacientes com granulomatose de Wegener
Santana, A. N. C. (2008) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2008.tde-10102008-152122
Antithrombotic Therapy in Venous Thrombosis and Pulmonary Embolism
Nisio, M. D., & Buller, H. R. (2012) · Wiley eBooks · doi:10.1002/9781118410875.ch21
[Use of warfarin and low range INR in the prevention of recurrent venous thrombosis].
Quintero, J., Torres, E., Diez‐Ewald, M., Arteaga-Vizcaíno, M., Vizcaíno, G., Leon, M. D., Rodríguez, Z., & Fernández, N. (2011) · PubMed
Behandlung bei akuter tiefer Beinvenenthrombose und Pulmonalembolie
Cr, C. (2014) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Therapy of Pulmonary Thromboembolism: an Evidence‐Based Approach
Riedel, M. (2005) · Wiley eBooks · doi:10.1002/9780470987377.ch40
Antikoagulation zur Sekundärprävention
Weil, J., & Schunkert, H. (2006) · Der Internist · doi:10.1007/s00108-006-1645-4
Mujer de 51 a?os con sospecha de trombosis venosa profunda
Antn, M. P. S., Snchez, J. F., Villamediana, R. L., & Hernando, E. R. (2004) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(04)70223-4
Long-Term Management of Venous Thromboembolism: Strategies for Reducing the Risk of Recurrence
Piazza, G., Hohlfelder, B., & Goldhaber, S. Z. (2015) · Springer eBooks · doi:10.1007/978-3-319-20843-5_10
Self-citation
Venenthrombose und Lungenembolie
Beyer, J., & Schellong, S. (2005) · Herz · doi:10.1007/s00059-005-2672-y
Chapitre 31 – Thérapeutique de la thrombose veineuse profonde
Élias, A., & Pernod, G. (2015) · doi:10.1016/b978-2-294-74489-1.00031-0
Quelle durée de traitement pour la maladie veineuse thrombo‐embolique ?
Fiessinger, J. (2003) · Sang thrombose vaisseaux
Ischaemic stroke in chagasic patients.
Teixeira, A. L., & Teixeira, M. M. (2004) · PubMed Central
Venous thromboembolism: acute diagnostic assessment and follow-up
Laiho, M. K. (2014) · Työväentutkimus Vuosikirja
Epidemiología de las tromboembolias pulmonares asintomáticas en los pacientes con cáncer
Pardo, J. R. P., Capitán, M. D. C. F., Rodriguez, M. L., & López, M. A. (2005) · Medicina Clínica · doi:10.1157/13073226
Is Lifelong Anticoagulation Worth the Risk in Patients With Unprovoked DVT?
Cortese, F. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-11-200912010-00027
Experience Always Wins the Day: Measure of Warfarin Anticoagulation Efficiency in the Internal Medicine Clinic
Nguyen, T. H. L., Belzile, N., Durand, M., Leroux‐Stewart, J., Thebeau, S., Landon‐Cardinal, O., Wistaff, R., Nguyen, P.-V., Lamarre-Cliché, M., Kolan, C., et al. (2013) · Journal of Hematology
Conventional Treatment of Deep Venous Thrombosis
Pineo, G. F., & Hull, R. D. (2007) · Elsevier eBooks · doi:10.1016/b978-012369515-4/50046-6
A 10 mg nomogram was more effective than a 5 mg nomogram for warfarin induction in outpatient venous thromboembolism
Beyth, R. J. (2003) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.8.6.173
Quel suivi proposer après la première embolie pulmonaire ?
Leroyer, C., Pigearias, B., & Sanchez, O. (2009) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(09)72485-1
Reconocer y tratar TVP la trombosis venosa profunda
Day, M. W. (2004) · Nursing (Ed española) · doi:10.1016/s0212-5382(04)71550-2
Fibrinolysis – new perspectives Fibrinolysis-neue Perspektiven
Schambeck, C. M. (2005) · Journal of Laboratory Medicine · doi:10.1515/jlm.2005.053
Risk for Venous Thromboembolism in Patients With Superficial Venous Thrombosis
Valsecchi, M. E. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-1-201007060-00025
Ximelagatran for Treatment and Prophylaxis of Recurrent Events in Deep Vein Thrombosis
Koscielny, J., Kiesewetter, H., Jörg, I., & Harenberg, J. (2007) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029607302561
Subclavian vein thrombosis: A case report and review of the literature
Miltiadous, G. A., Liamis, G. L., Metafratzi, Z. M., Vartholomatos, G., Kolaitis, N., & Elisaf, M. (2004) · International Journal of Angiology · doi:10.1007/s00547-004-1035-5

Authors: Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., Paulson, R., Wong, T., Bauer, K. A., Schwartz, B. A., Miletich, J. P., Bounameaux, H., & Glynn, R. J.
Affiliations: Brigham and Women's Hospital (US)
National Institutes of Health (US)
Washington University in St. Louis (US)
Cleveland Clinic (US)
University of Vermont (US)
University of North Carolina at Chapel Hill (US)
Georgetown University Medical Center (US)
LDS Hospital (US)
Altru Health System (US)
St. Boniface Hospital (CA)
Beth Israel Deaconess Medical Center (US)
University Hospital of Geneva (CH)
ORCID: Ridker, Paul M
Goldhaber, Samuel Z.
Rosenberg, Yves
Cushman, Mary
Moll, Stephan
Kessler, Craig M.
Elliott, C. Gregory
Bauer, Kenneth A.
Bounameaux, Henri
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2003-04-10
Volume: 348
Issue: 15
Pages: 1425-1434
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa035029
OpenAlex: W2112757583
Cited by: 808
References: 29
Citations by year: 2026: 3 · 2025: 9 · 2024: 5 · 2023: 7 · 2022: 10 · 2021: 13 · 2020: 16 · 2019: 23 · 2018: 16 · 2017: 19 · 2016: 25 · 2015: 24 · 2014: 45 · 2013: 38 · 2012: 44
FWCI: 53.42
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords: recurrent venous thromboembolism, long-term anticoagulation, idiopathic venous thromboembolism, major bleeding, inherited thrombophilia, international normalized ratio, benefit-risk balance
MeSH terms: Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Risk, Thromboembolism, Warfarin, International Normalized Ratio, Venous Thrombosis, Stroke, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks